

Datasheet for 200-301-H93**MITF Antibody****Overview**

Description:	Anti-MITF (MOUSE) Monoclonal Antibody - 200-301-H93
Item No.:	200-301-H93
Size:	100 µg
Applications:	IF, IHC, WB
Reactivity:	Human
Host Species:	Mouse

Product Details

Background:	Anti-MITF antibody detects human MITF. Microphthalmia-associated bHLH-LZ transcription factor (MITF) is a positively acting transcription factor containing a transcription activation domain and a bHLH-LZ domain that mediates DNA-binding and dimerization. Both the transcription activation and bHLH-LZ domains are highly conserved in the closely related TFE3, TFEB and TFEC. MITF can form heterodimers in vitro with the above transcription factors, but not with other bHLH-LZ factors such as Myc, Max or USF. MITF is expressed as multiple isoforms, which share common activation and DNA-binding domains, but differ in the amino-terminal region. MITF is targeted by three kinases: GSK-3beta, Map kinase ERK2 and members of the p90 Rsk family of kinases. Anti-MITF antibody is ideal for investigators involved in kinase, phosphatase, NFkappaB, and signaling research.
Synonyms:	BHLHE32, Microphthalmia-associated transcription factor, Class E basic helix-loop-helix protein 32, bHLHe32
Host Species:	Mouse
Clonality:	Monoclonal
Clone ID:	21D1418
Format:	IgG1

Target Details

Gene Name:	MITF
Reactivity:	Human

Immunogen Type:	Conjugated Peptide
Immunogen:	MITF Antibody was produced in mice prepared by repeated immunizations with a synthetic peptide (sequence PSTGLCSPDLVN) corresponding to internal amino acids with human MITF protein.
Purity/Specificity:	Anti-MITF Antibody was purified by Protein G chromatography. A BLAST analysis was used to suggest cross-reactivity with MITF from Human, Rat, and Mouse based on 100% homology with the immunizing sequence. Cross-reactivity with Anti-MITF from other sources has not been determined.
Relevant Links:	• UniProtKB - O75030 • NCBI - NP_000239.1 • GeneID - 4286

Application Details

Tested Applications:	IF, IHC, WB
Application Note:	Anti-MITF antibody is tested for WB, IHC-P, and IF. Expect a band approximately 52kDa on specific lysates. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
WB:	3-5 µg/mL

Formulation

Physical State:	Liquid
Concentration:	1.0 mg/ml by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.05% (w/v) Sodium Azide
Stabilizer:	0.05% BSA


Shipping & Handling

Shipping Condition:	Dry Ice
----------------------------	---------

Storage Condition: Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Expiration: Expiration date is one (1) year from date of receipt.

Images



Western Blot

Western Blot of Mouse Anti-MITF antibody. Lane A: MITF in A375 lysate. Primary antibody: MITF antibody at 4 µg/mL for overnight at 4°C. Secondary antibody: IRDye800™ mouse secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: 45 kDa for Livin BIRC7 KIAP. Other band(s): none.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.